Continuous Glucose Monitoring Metrics and Hemoglobin A1c Relationship in Patients with Type 2 Diabetes Treated by Hemodialysis.

Rodolfo J Galindo, Bobak Moazzami, Katherine R Tuttle, Richard M Bergenstal, Limin Peng, Guillermo E Umpierrez
Author Information
  1. Rodolfo J Galindo: Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA. ORCID
  2. Bobak Moazzami: Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia, USA.
  3. Katherine R Tuttle: Division of Nephrology, Kidney Research Institute, and Institute of Translational Health Sciences, University of Washington, Seattle, Washington, USA.
  4. Richard M Bergenstal: International Diabetes Center, HealthPartners Institute, Minneapolis, Minnesota, USA. ORCID
  5. Limin Peng: Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
  6. Guillermo E Umpierrez: Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia, USA.

Abstract

There is a need for accurate glycemic control metrics in patients with diabetes and end-stage kidney disease (ESKD). Hence, we assessed the relationship of continuous glucose monitoring (CGM) metrics and laboratory-measured hemoglobin A1c (HbA1c) in patients with type 2 diabetes (T2D) treated by hemodialysis. This prospective observational study included adults (age 18-80 years) with T2D (HbA1c 5%-12%), treated by hemodialysis (for at least 90 days). Participants used a Dexcom G6 Pro CGM for 10 days. Correlation analyses between CGM metrics [mean glucose, glucose management indicator (GMI), and time-in-range (TIR 70-180 mg/dL)] and HbA1c were performed. Among 59 participants (mean age was 57.7 ± 9.3 years, 58% were female, 86% were non-Hispanic blacks), the CGM mean glucose level was 188.9 ± 45 mg/dL (95% CI: 177.2, 200.7), the mean HbA1c and GMI were 7.1% ± 1.3% and 7.8% ± 1.1%, respectively (difference 0.74% ± 0.95). GMI had a strong negative correlation with TIR 70-180 mg/dL (r = -0.96). The correlation between GMI and HbA1c (r = 0.68) was moderate. Up to 29% of participants had a discordance between HbA1c and GMI of <0.5%, with 22% having a discordance between 0.5% and 1%, and 49% having a discordance of >1%. In patients with diabetes and ESKD treated by hemodialysis, the GMI has a strong correlation with TIR, while HbA1c underestimated the average glucose and GMI. Given the limitations of HbA1c in this population, GMI or mean glucose and TIR may be considered as more appropriate glucose control markers.

Keywords

References

  1. Ann Intern Med. 2017 Jul 18;167(2):95-102 [PMID: 28605777]
  2. Kidney Int Rep. 2022 Sep 29;7(12):2589-2607 [PMID: 36506243]
  3. Diabetes Care. 2022 Jul 7;45(7):1666-1669 [PMID: 35485908]
  4. Diabetes Care. 2021 Jul;44(7):1641-1646 [PMID: 34099515]
  5. Diabetes Technol Ther. 2019 Feb;21(2):81-85 [PMID: 30575414]
  6. BMJ Open Diabetes Res Care. 2022 Jan;10(1): [PMID: 34980591]
  7. J Diabetes Sci Technol. 2020 Jan;14(1):83-86 [PMID: 30943780]
  8. Am J Kidney Dis. 2011 Oct;58(4):591-8 [PMID: 21715072]
  9. Endocr Pract. 2023 Nov;29(11):919-927 [PMID: 37369291]
  10. Lancet Diabetes Endocrinol. 2023 Jan;11(1):42-57 [PMID: 36493795]
  11. Diabetes Care. 2017 Aug;40(8):994-999 [PMID: 28733374]
  12. Diabetes Care. 2017 Jul;40(7):832-838 [PMID: 28039172]
  13. Diabetes Care. 2024 Feb 1;47(2):267-271 [PMID: 38085705]
  14. Diabetes Technol Ther. 2021 Apr;23(4):253-258 [PMID: 33253015]
  15. Diabetes Care. 2019 Aug;42(8):1593-1603 [PMID: 31177185]
  16. Diabetes Res Clin Pract. 2020 Dec;170:108502 [PMID: 33065179]
  17. Am J Nephrol. 2008;28(5):732-43 [PMID: 18434712]
  18. Diabetes Care. 2022 Jan 1;45(1):100-107 [PMID: 34740910]
  19. Endocr Rev. 2020 Oct 1;41(5): [PMID: 32455432]
  20. Diabetes Technol Ther. 2018 Apr;20(4):314-316 [PMID: 29565197]
  21. Diabetes Care. 2010 Nov;33(11):2310-3 [PMID: 20798337]
  22. Diabetes Care. 2018 Nov;41(11):2275-2280 [PMID: 30224348]
  23. Diabetes Care. 2022 Dec 1;45(12):3075-3090 [PMID: 36189689]
  24. Diabetes Technol Ther. 2023 Feb;25(2):148-150 [PMID: 36130138]
  25. Clin Chem. 2023 Apr 3;69(4):422-428 [PMID: 36738249]
  26. Clin J Am Soc Nephrol. 2023 Jan 1;18(1):130-145 [PMID: 36719162]

Grants

  1. R01 DK136023/NIDDK NIH HHS

MeSH Term

Humans
Diabetes Mellitus, Type 2
Middle Aged
Female
Glycated Hemoglobin
Male
Renal Dialysis
Aged
Prospective Studies
Blood Glucose
Blood Glucose Self-Monitoring
Adult
Kidney Failure, Chronic
Glycemic Control
Aged, 80 and over
Young Adult
Continuous Glucose Monitoring

Chemicals

Glycated Hemoglobin
Blood Glucose
hemoglobin A1c protein, human

Word Cloud

Created with Highcharts 10.0.0GMIHbA1cglucoseCGMdiabeteshemodialysisTIRmean0metricspatients2treatedmg/dL7correlationdiscordancecontrolend-stagekidneydiseaseESKDA1cT2Dageyearsdays70-180participants±1%strongr=5%needaccurateglycemicHenceassessedrelationshipcontinuousmonitoringlaboratory-measuredhemoglobintypeprospectiveobservationalstudyincludedadults18-805%-12%least90ParticipantsusedDexcomG6Pro10Correlationanalyses[meanmanagementindicatortime-in-range]performedAmong59577 ± 9358%female86%non-Hispanicblackslevel18894595%CI:1772001% ± 13%8% ± 1respectivelydifference74%95negative-09668moderate29%<022%49%>1%underestimatedaverageGivenlimitationspopulationmayconsideredappropriatemarkersContinuousGlucoseMonitoringMetricsHemoglobinRelationshipPatientsTypeDiabetesTreatedHemodialysis

Similar Articles

Cited By